Introduction
============

Lumbar degenerative spondylolisthesis (LDS) is one of the most common lumbar spinal diseases associated with low back pain, radiculopathy, and neurogenic intermittent claudication.[@JR1500134-1] The pathogenesis of lumbar spondylolisthesis begins with the slipping of one vertebral body over the other, narrowing the spinal canal and leading to a wide range of clinical presentations.[@JR1500134-2] Currently, patients with LDS have treatment options that range from conservative (nonsteroidal anti-inflammatory drugs, physical therapy, epidural steroid injection and bracing) to surgical (decompressive laminectomy with or without fusion and instrumentation).[@JR1500134-3] [@JR1500134-4] When conservative treatments fail to provide relief for severe lumbar spondylolisthesis, decompression and fusion can be considered.[@JR1500134-5] There are several surgical approaches for segmental fusion, including anterior lumbar interbody fusion (ALIF), posterolateral fusion (PL), posterolateral plus posterior interbody fusion (PLPIF), and posterior interbody fusion (PIF).[@JR1500134-6] [@JR1500134-7] [@JR1500134-8] To promote the fusion rates, pedicle screw instrumentation, bone graft material, and osteoinductive adjuvants are used.[@JR1500134-9] [@JR1500134-10]

Human recombinant bone morphogenetic protein (rhBMP)-2 and rhBMP-7 have been used as osteoinductive adjuvants for spinal fusion.[@JR1500134-11] [@JR1500134-12] Commercially available rhBMP-2 (INFUSE Bone Graft, Medtronic, Memphis, Tennessee, United States) has been approved for use in ALIF with a threaded interbody cage. Due to the rhBMP-2 osteogenic potential, off-label use has been extended to PL, PIF, and PLPIF.[@JR1500134-9] [@JR1500134-13] [@JR1500134-14]

Although use of rhBMP-2 leads to high fusion rates, complications including excessive and ectopic bone formation, carcinogenicity, bone resorption, neuritis, seroma formation, retrograde ejaculation, and dural ossification leading to neural impingement have been reported.[@JR1500134-13] [@JR1500134-15] [@JR1500134-16] [@JR1500134-17]

Due to the large variations in spine procedures across the United States, it is essential to understand the use of rhBMP-2 in the surgical management of LDS and how its use is affected by different fusion procedures and patient demographics. It is also unclear whether the presence of rhBMP-2 could decrease the reoperation rate. To gain a better understanding, we examined retrospective data on patients treated for LDS with rhBMP-2 in the United States Medicare population from 2005 to 2011.

Materials and Methods
=====================

For our retrospective study, we used the PearlDiver Patient Record Database (available at [www.pearldiverinc.com](www.pearldiverinc.com); PearlDiver Inc., Fort Wayne, Indiana, United States). Our Institutional Review Board deemed this study exempt from review, as all patient information was deidentified. In our study, we used orthopedic billing records from the standard analytical files from Medicare, containing more than 40 million patients per year. The database was queried for patients undergoing surgical fusion for LDS from 2005 through 2011. Patients were identified by entry of *International Classification of Diseases*, ninth edition (ICD-9) diagnosis code 738.4 for LS and 84.52 for bone morphogenetic protein. The number of patients having a record of Current Procedural Terminology (CPT) codes associated with ALIF/lateral lumbar interbody fusion (LLIF), PL, PIF, PLPIF, or reoperation lumbar fusion were recorded, including CPT-22558 (the ALIF code is also used for commonly performed LLIF, also known as eXtreme Lateral Interbody Fusion or Direct Lateral Interbody Fusion), CPT-22585, CPT-22586, CPT-22845, CPT-22614, CPT-22634, CPT-22632, and CPT-22849 ([Table 1](#TB1500134-1){ref-type="table"}). The search results yielded the number of patients divided by year, gender, age group (less than 65, 65 to 69, 70 to 74, 75 to 79, 80 to 84, and greater than 84), and geographic region of the United States (Northeast, South, Midwest, West). Bone morphogenetic protein use rate (BR) and per year bone morphogenetic protein use rate (PYBR) were calculated for each group. Patients were followed for up to 3 years to permit assessment of long-term outcome.

###### ICD-9 Procedure codes and CPT codes searched in the PearlDiver database

  Code     Diagnosis/procedure
  -------- ------------------------------------------------------------------------------------------------------------------------
  ICD-9    
   738.4   Acquired spondylolisthesis (degenerative spondylolisthesis; spondylolisthesis acquired excludes congenital \[756.12\])
   84.52   BMP
  CPT      
   22558   Anterior approach for lumbar fusion or lumbar lateral interbody
   22585   Each additional interspace (use with 22558)
   22586   Arthrodesis presacral interbody technique
   22845   Anterior instrumentation; 2--3 vertebral segments
   22614   Posterior or posterolateral technique for fusion/arthrodesis
   22634   A combined posterior or posterolateral technique with posterior interbody arthrodesis at an additional level
   22632   Arthrodesis an additional level fusion
   22849   Reoperation lumbar fusion (reinsertion of spine)

Abbreviations: BMP, bone morphogenetic protein; CPT, Current Procedural Terminology; ICD-9, *International Classification of Diseases*, ninth edition.

For statistical analysis, we used SPSS 13.0 software (IBM, Armonk, New York, United States). The chi-square test was used to determine statistical significance with regard to procedure, gender, age, and region. Linear regression was performed to test the significance of trends over time. The level of significance was *p* \< 0.05.

Results
=======

Between 2005 and 2011, there were 11,335 fusion surgeries in patients with LDS, of which 3,461 cases were performed with the use of rhBMP-2. Within the rhBMP-2 cases, there were 2,410 female and 1,082 male patients. Nine hundred fifty-three surgeries with rhBMP-2 were done in the Midwest, 271 in the Northeast, 1,314 in the South, and 975 in the West. The overall distribution of rhBMP-2 use by age was 559 cases in patients less than 65 years old, 1,035 cases in patients 65 to 69 years old, 930 cases in patients 70 to 74 years old, 655 cases in patients 75 to 79 years old, 241 cases in patients 80 to 84 years old, and 78 cases in patients greater than 84 years old.

Per Year Bone Morphogenetic Protein Use Rate
--------------------------------------------

### By Year

Overall, the average PYBR was 30.5% between 2005 and 2011. Although there was a significant decrease in 2010 (24.9%, *p* \< 0.0001), in 2011 PYBR increased to 30.5%, coming close to the 7-year average (30.5%, [Table 2](#TB1500134-2){ref-type="table"}).

###### The number of patients with or without BMP and PYBR from 2005 to 2011

                                                      2005    2006    2007    2008    2009    2010    2011    Total
  --------------------------------------------------- ------- ------- ------- ------- ------- ------- ------- --------
  BMP cases[a](#FN1500134-3){ref-type="table-fn"}     388     411     491     588     671     395     568     3,461
  Total cases[b](#FN1500134-4){ref-type="table-fn"}   1,338   1,354   1,546   1,784   2,106   1,587   1,863   11,335
  PYRB (%)[c](#FN1500134-5){ref-type="table-fn"}      29.00   30.35   31.76   32.96   31.86   24.89   30.49   30.53

Abbreviations: BMP, bone morphogenetic protein; PYBR, per year bone morphogenetic protein use rate.

Number of patients with lumbar degenerative spondylolisthesis using BMP in the operation.

Total number of patients with lumbar degenerative spondylolisthesis treated by operation.

BMP cases in 1 year/total cases in 1 year × 100 (%).

### By Surgical Procedure

The mean PYBR of each procedure was 22.4% for ALIF, 29.2% for PL, 34.3% for PLPIF, and 34.5% for PIF from 2005 to 2011. The trend of PYBR for each procedure increased from 2005 to 2008 and was lowest in 2010 ([Fig. 1a](#FI1500134-1){ref-type="fig"}). The yearly distribution of surgical procedures using rhBMP-2 was the greatest in PL, followed by PLPIF, PIF, and ALIF ([Fig. 1b](#FI1500134-1){ref-type="fig"}).

![Bone morphogenetic protein use in different surgical procedures. (a) PYBR in for each produce from 2005 and 2011 with PIF (34.53%) having the highest mean PYBR of the four procedures; (b) the proportion of each procedure cases by year from 2005 to 2011. Abbreviations: ALIF, anterior lumbar interbody fusion; PIF, posterior interbody fusion; PL, posterolateral fusion; PLIF, posterolateral plus posterior interbody fusion; PYBR, per year bone morphogenetic protein use rate; rh-BMP2, recombinant human bone morphogenetic protein-2.](10-1055-s-0036-1580735-i1500134-1){#FI1500134-1}

Bone Morphogenetic Protein Use Rate
-----------------------------------

### By Age

The overall rate of rhBMP-2 use changed with age, with the lowest rate (27.1%) observed in patient 80 to 84 years old, followed by patients less than 65 years (29.1%), 75 to 79 years old (30.9%), greater than 84 years old (31.1%), 70 to 74 years old (31.2%), and 65 to 69 years old (31.3%, [Table 3](#TB1500134-3){ref-type="table"}). Looking at the age distribution by fusion type, the highest rate of rhBMP-2 use for ALIF, PLPIF, and PIF was in patients \> 84 years of age (31.4, 39.7, and 46.2%, *p* \< 0.001, respectively). The greatest rhBMP-2 use for PL was found in patients 65 to 69 years old (30.6%, *p* \< 0.001, [Table 3](#TB1500134-3){ref-type="table"}).

###### The number of patients using or without BMP of different surgical techniques by age

           ALIF    PL    PLPIF   PIF     Total                                                                       
  -------- ------- ----- ------- ------- ------- ------- ------- ------- ------- ----- ----- ------- ------- ------- -------
  \<65     303     81    21.09   493     204     29.27   455     207     31.27   114   67    37.02   1,365   559     29.05
  65--69   353     92    20.67   927     409     30.61   763     404     34.62   234   130   35.71   2,277   1,035   31.25
  70--74   250     82    24.7    931     403     30.21   646     338     34.35   221   107   32.62   2,048   930     31.23
  75--79   166     54    24.55   746     303     28.88   413     226     35.37   138   72    34.29   1,463   655     30.93
  80--84   68      15    18.07   384     122     24.11   144     82      36.28   52    22    29.73   648     241     27.11
  \>84     24      11    31.43   104     36      25.71   38      25      39.68   7     6     46.15   173     78      31.08
  Total    1,164   335   22.35   3,585   1,477   29.18   2,459   1,282   34.27   766   404   34.53                   

Abbreviations: ALIF, anterior lumbar interbody fusion; B, number of patients using BMP; BMP, bone morphogenetic protein; PIF, posterior interbody fusion; PL, posterolateral fusion; PLIF, posterolateral plus posterior interbody fusion; N, number of patients not using BMP; R, ratio of BMP use = B/(N + B) × 100 (%) of each procedure for every age.

### By Demographic Region

The BR was the highest in the West (37.3%) followed by the Midwest (32.8%), the South (28.3%), and the Northeast (19.7%, *p* \< 0.001; [Fig. 2a](#FI1500134-2){ref-type="fig"}).When examining the regional BR per procedure, we observed an uneven distribution ([Fig. 2b](#FI1500134-2){ref-type="fig"}). The lowest BR for ALIF was found in the South (18.4%), and the Northeast region had the lowest BR for PL (16.2%), PLPIF (26.3%), and PIF (23.8%).

![The BMP use rate by demographic region. (a) The PYBR of the four regions. West region had the highest PYBR among four regions with the mean PYBR of 37.33%. (b) The distribution of BMP use by the four procedures in each region. Abbreviations: ALIF, anterior lumbar interbody fusion; BMP, bone morphogenetic protein; PIF, posterior interbody fusion; PL, posterolateral fusion; PLIF, posterolateral plus posterior interbody fusion; PYBR, per year bone morphogenetic protein use rate.](10-1055-s-0036-1580735-i1500134-2){#FI1500134-2}

### By Gender

We found that the BR was higher in female patients in all years except 2008 and 2009. In those 2 years, male patients were more likely to receive rhBMP2 compared with the female patients (2008: male 35.2%, female 32.1%; 2009: male 33.3%, female 31.2%; *p* \< 0.0001, [Table 4](#TB1500134-4){ref-type="table"}).

###### The number of patients using or not using BMP by sex from 2005 to 2011

           2005    2006    2007    2008    2009    2010    2011
  -------- ------- ------- ------- ------- ------- ------- -------
  Female                                                   
   N       649     647     707     779     980     800     856
   B       283     301     348     368     444     272     394
   R (%)   30.36   31.75   32.99   32.08   31.18   25.37   31.52
  Male                                                     
   N       301     296     348     369     455     392     439
   B       105     110     143     200     227     123     174
   R (%)   25.86   27.09   29.12   35.15   33.28   23.88   28.38

Abbreviations: B, number of patients using BMP; BMP, bone morphogenetic protein; N, number of patients not using BMP; R, ratio of BMP use = B/(N + B) × 100 (%) of each procedure for every age.

Reoperation Rate of Patients with or without Bone Morphogenetic Protein
-----------------------------------------------------------------------

From 2005 to 2011, the overall reoperation rate of patients who used rhBMP-2 was significantly lower than the rate in patients who did not use rhBMP-2 (0.7 versus 1.1%, *p* \< 0.0001, [Fig. 3](#FI1500134-3){ref-type="fig"}). Furthermore, the same pattern was seen looking at the reoperation rates in different procedures with and without rhBMP-2: ALIF (0 versus 1%, *p* \< 0.0001), PL (0.8 versus 1%, *p* \< 0.001), PLPIF (0.9 versus 1.2%, *p* \< 0.01), and PIF (0.3 versus 0.9%, *p* \< 0.0001).

![The reoperation rate by 3-year follow-up. From 2005 to 2008, patients using bone morphogenetic protein (BMP) had a lower reoperation rate in each year compared with patients not using BMP (1.29 and 2.21%, respectively, in 2005, *p* \< 0.0001; 1.70 and 2.55%, respectively, in 2006, *p* \< 0.0001; 1.63 and 3.03%, respectively, in 2007, *p* \< 0.0001; 2.72 and 3.76%, respectively, in 2008, *p* \< 0.001).](10-1055-s-0036-1580735-i1500134-3){#FI1500134-3}

Discussion
==========

LDS affects between 0.5 and 4.5% of the adult population, especially patients over the age of 60.[@JR1500134-3] [@JR1500134-7] [@JR1500134-18] In general, nerve decompression and fusion is the most effective surgical intervention. Even though isolated posterior and anterior approaches are the most common procedures, combined anterior-posterior or posterior interbody techniques may provide an optimal reconstruction for patients with severe pathology.[@JR1500134-18] [@JR1500134-19] [@JR1500134-20] [@JR1500134-21] [@JR1500134-22]

rhBMP-2 and its osteogenic potential were first reported by Urist in 1965.[@JR1500134-23] Studies focusing on various approaches and carriers have demonstrated the regenerative potential of rhBMP-2 in enhancing segmental fusion.[@JR1500134-24] [@JR1500134-25] [@JR1500134-26] Although a large body of literature favors the use of rhBMP-2, some studies indicate potential adverse effects.[@JR1500134-16] [@JR1500134-17] [@JR1500134-27]

In the present study, patients using rhBMP-2 had a significantly lower reoperation rate within a 7-year period compared with patients who did not use rhBMP-2. Even though the effect of rhBMP-2 was positive, we found that the PYBR changed in the 7 years, with an upward trend from 2005 to 2008 and a decrease in 2010, which may be due to the Food and Drug Administration notification and published reports on complications on bone morphogenetic protein use.

In all patients with LDS, rhBMP-2 was used mainly for posterior and posterior-lateral procedures, compared with the on-label indication (ALIF). This result could be potentially explained with the increased use of the posterior approach for various spinal degenerative conditions, as well as high fusion rates, good patient outcomes, and restoration of sagittal balance in patients with spondylolisthesis.[@JR1500134-28] [@JR1500134-29]

Previous studies found that the differences in LDS treatment with patient age were a result of various general conditions, tolerance to trauma after the surgery, bone density, and degree of degeneration.[@JR1500134-13] [@JR1500134-14] [@JR1500134-30] Similarly, in our study, the use of rhBMP-2 in LDS treatment showed no linear correlation with age. It is unclear why certain age groups had high rhBMP-2 rates and if the patient profiles within the database had influence.

In our study, we observed PYBR changes associated with gender, with female patients having more rhBMP-2 procedures than male patients. Earlier studies on idiopathic scoliosis demonstrated that use of rhBMP-2 was more common in the West region.[@JR1500134-31] Similarly, we found the West region to have the highest rate of rhBMP-2 use for the LDS treatments. However, the distribution of the four fusion procedures in each region was not the same. The possible explanation may be regional variations in surgeon preference and training, economic factors, and patient expectations.

Although this study provides a timely and critical update on the trends of rhBMP-2 use, there are several limitations to this study. The database has been reported to carry a potential risk for inaccuracy in capturing the correct diagnoses and procedures. The variations in coding and data input may introduce additional inaccuracies in patient selections from the database. To address these limitations, we first utilized the procedural codes and then the diagnostic codes to improve the specificity of our search. In addition, the total number of cases over the 7-year period did not match the sum of number of cases per year, which happens if patients get older, if they relocate, or if they had more than one operation between 2005 and 2011; in those instances, they will be counted in the database for several years. To address these limitations, we calculated the total number of each parameter by the output of the PearlDiver database without double-count. Furthermore, we were unable to comment on the effect of bone morphogenetic protein dose with various procedures due to the inexistence of dose-specific ICD-9 codes. Finally, in our study, the follow-up period was 3 years, but it is possible that these results would change over a longer period. Despite these limitations, we believe that our data represents important and relevant information on the trends of rhBMP-2 use for the treatment of LDS.

Conclusion
==========

Our study shows that the utilization of rhBMP-2 for the LDS treatment varied by year, region, gender, and type of fusion technique. Patients age 60 to 65 years old and patients in the West had more procedures with rhBMP-2. The reoperation rate of patients using rhBMP-2 was significantly lower than in patients not using rhBMP-2. Further studies on lumbar spondylolisthesis looking at the geographic variability, a longer follow-up, and the cost profile of rhBMP-2 utilization are needed.
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